Rethinking the Blood–Brain Barrier: Integrating Lymphatic Pathways to Resolve Paradoxes in Neurodegeneration

2026

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.4103/wkrj.wkrj_23_26
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

A BSTRACT This review synthesizes emerging evidence underlying apparent blood–brain barrier paradoxes and proposes an expanded conceptual framework incorporating vascular and lymphatic components in aging, inflammation, and neurodegeneration. A structured literature review of peer-reviewed studies and authoritative reviews published between 2016 and 2026, with selected foundational studies, was conducted across major biomedical databases. Accumulating evidence indicates that blood–brain barrier function is governed by regulated transport processes, endothelial signaling, and pericyte-dependent regulation. Human imaging and cerebrospinal fluid biomarker studies reveal early, region-specific barrier dysfunction associated with cognitive impairment and APOE4-related risk. However, several paradoxes, including protein accumulation, immune trafficking, and microplastic retention, cannot be fully explained by blood–brain barrier dynamics alone. Emerging evidence of lymphatic vessels within brain parenchyma suggests a complementary clearance system, indicating that these paradoxes may reflect combined dysregulation of vascular entry and lymphatic drainage. The blood–brain barrier should therefore be reconceptualized not as an isolated barrier but as part of an integrated neurovascular–lymphatic interface, with important implications for biomarkers, diagnosis, and mechanism-based therapies in neurodegenerative disease.